EFFICIENCY OF SILDANEFIL MONOTHERAPY IN BENIGN PROSTATIC HYPERPLASIA

Area of Science:

• Urology
• Pharmacology

Background:

• Benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS) present significant socioeconomic challenges.
• Phosphodiesterase type 5 inhibitors show promise in BPH/LUTS treatment, but further research is needed.
• Sildenafil is being investigated for its efficacy in managing BPH/LUTS.

Purpose of the Study:

• To evaluate the effects of sildenafil on International Prostate Symptom Score (IPSS), post-voiding residuum (PVR), and maximal urine flow rate (Qmax) in patients with BPH/LUTS.

Main Methods:

• A prospective, controlled, open-label, randomized study involving 30 male patients over 45 years old with BPH/LUTS.
• Patients met inclusion criteria including IPSS > 3, prostate-specific antigen < 10 ng/mL, and normal urinalysis.
• Regular assessments of IPSS, PVR, and Qmax were conducted during the study period.

Main Results:

• Sildenafil treatment led to a statistically significant improvement in mean IPSS from 12.8 to 8.6 (32.8% reduction).
• Mean PVR significantly decreased from 49.4 ml to 40.2 ml (18.6% reduction).
• Mean Qmax showed a statistically significant increase from 11.8 ml/s to 12.8 ml/s (8.5% increase).

Conclusions:

• Continuous low-dose sildenafil appears to be a viable treatment option for mild to moderate BPH/LUTS.
• Sildenafil may be particularly beneficial for patients with concurrent erectile dysfunction.
• This study contributes to understanding the role of sildenafil in BPH/LUTS management, despite its small sample size.